List of Excipients in Branded Drug BACTERIOSTATIC WATER

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	BACTERIOSTATIC WATER	bacteriostatic water	0409-3977	BENZYL ALCOHOL
HF Acquisition Co LLC DBA HealthFirst	BACTERIOSTATIC WATER	bacteriostatic water	51662-1473	BENZYL ALCOHOL
US MedSource LLC	BACTERIOSTATIC WATER	water	61699-3977	BENZYL ALCOHOL
REMEDYREPACK INC	BACTERIOSTATIC WATER	bacteriostatic water	70518-1236	BENZYL ALCOHOL
Medical Purchasing Solutions LLC	BACTERIOSTATIC WATER	water	71872-7129	BENZYL ALCOHOL

Bacteriostatic Water Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Bacteriostatic Water for Injection, USP is a preserved sterile-water drug product, not a conventional active pharmaceutical ingredient. Its commercial value comes from reliable parenteral-grade water, controlled benzyl alcohol content, container compatibility, and availability in multi-dose presentations. The patent estate is generally weak because the core composition is established, compendial, and difficult to differentiate through composition claims. Commercial opportunities are concentrated in supply reliability, packaging, device compatibility, global regulatory execution, and specialized diluent systems.

What is Bacteriostatic Water for Injection?

Bacteriostatic Water for Injection is sterile water containing a bacteriostatic preservative, typically 0.9% benzyl alcohol. It is used to dilute or dissolve injectable drugs before administration when the drug manufacturer permits that diluent. The product is supplied in multi-dose containers and is administered only after the appropriate drug has been added.

The product differs from Sterile Water for Injection in one material respect:

Attribute	Bacteriostatic Water for Injection	Sterile Water for Injection
Preservative	Usually 0.9% benzyl alcohol	None
Container use	Multi-dose use permitted under labeling	Generally single-dose use
Primary function	Diluent with antimicrobial preservation	Preservative-free diluent
Neonatal suitability	Generally unsuitable because of benzyl alcohol	Preferred where clinically appropriate
Intrathecal use	Contraindicated unless specifically authorized	Product-specific; preservative-free status is required
Differentiation	Preservative concentration, container, fill size, compatibility	Sterility, container, and presentation

Benzyl alcohol is an excipient with antimicrobial activity. It is not intended to provide complete sterility after repeated product access, and the product must be handled according to its labeling and applicable aseptic procedures. FDA labeling warns against use in neonates and against administration by routes for which benzyl alcohol is unsuitable. [1]

What excipients are used in Bacteriostatic Water?

The core formulation normally contains Water for Injection and benzyl alcohol at 0.9% v/v. The formulation strategy is intentionally narrow.

Core formulation

Component	Function	Commercial and regulatory relevance
Water for Injection	Vehicle and diluent	Must meet compendial and parenteral-quality requirements
Benzyl alcohol	Preservative	Drives neonatal, intrathecal, and route-of-administration restrictions
Container-closure system	Maintains sterility and supports repeated withdrawal	Affects extractables, leachables, stopper puncture performance, and shelf life

Additional excipients are generally undesirable because they can alter pH, osmolality, drug compatibility, injection tolerability, or the regulatory identity of the product. A manufacturer seeking a differentiated product should avoid unnecessary buffers, surfactants, chelators, or tonicity agents unless the product is designed as a specific diluent for a named injectable drug.

What is the best excipient strategy for Bacteriostatic Water?

The most defensible strategy is a minimal-excipient formulation with tight control of benzyl alcohol concentration and container compatibility.

Benzyl alcohol concentration

A concentration near the established 0.9% level provides the strongest regulatory and clinical precedent. Reducing the concentration could weaken antimicrobial preservation and require new preservative-effectiveness work. Increasing it could worsen toxicity, injection-site tolerability, and route restrictions.

A lower-benzyl-alcohol product could have commercial value for selected adult injectable applications, but it would create a new product-development burden:

• antimicrobial effectiveness testing;
• multidose in-use stability;
• preservative assay and degradation studies;
• compatibility testing with target drugs;
• clinical justification for the revised concentration;
• new regulatory review of the formulation and labeling.

The commercial case is strongest when the product is paired with a defined drug or device that has an established need for lower preservative exposure.

Preservative-free variants

A preservative-free presentation is commercially important but should be positioned as Sterile Water for Injection rather than Bacteriostatic Water. A manufacturer cannot obtain the primary benefit of bacteriostatic water, namely multidose preservation, while removing the preservative.

A product portfolio can therefore include:

1. Bacteriostatic Water for Injection for multi-dose adult use.
2. Sterile Water for Injection for neonatal, intrathecal, ophthalmic, or other preservative-sensitive uses.
3. Drug-specific diluent kits where the manufacturer controls the final reconstitution process.

This portfolio approach reduces the need to force one formulation into incompatible clinical settings.

Container-closure strategy

Packaging is a more promising differentiation area than composition. Relevant options include:

• 10 mL, 20 mL, and 30 mL vials;
• larger multi-dose vials for institutional use;
• polymer containers;
• glass vials with elastomeric closures;
• prefilled syringes for validated applications;
• dual-chamber or drug-diluent systems;
• tamper-evident and barcoded presentations.

Each format creates separate validation requirements. The critical tests include sterility maintenance, preservative loss, stopper coring, container interaction, extractables and leachables, light exposure, shipping robustness, and repeated puncture performance.

What FDA regulatory status applies to Bacteriostatic Water?

Bacteriostatic Water for Injection is regulated as a prescription sterile injectable product. FDA-approved labeling describes the product as a diluent for parenteral drugs and identifies benzyl alcohol as the bacteriostatic agent. The product is not an over-the-counter water product or a general-purpose laboratory reagent. [1]

The regulatory pathway depends on the proposed product and reference product. Potential routes include:

• an abbreviated application where an eligible reference product and regulatory pathway exist;
• a 505(b)(2) application for a product with formulation, container, presentation, or labeling differences;
• a full application if the sponsor proposes material clinical or formulation distinctions;
• a drug-device combination pathway for integrated reconstitution systems.

The intended use matters. A product labeled for general dilution has a different development profile from a product labeled for a particular injectable biologic, peptide, vaccine, or lyophilized drug.

FDA labeling constraints

The principal labeling constraints are:

• not for use in neonates;
• not for use by routes where benzyl alcohol is contraindicated;
• use only with drugs whose prescribing information permits the diluent;
• inspect for particulate matter and discoloration;
• discard unused contents according to the product label;
• avoid presenting the product as a therapeutic injectable.

FDA labeling also places responsibility on the user to verify compatibility between the diluent and the drug being reconstituted. [1]

What patents protect Bacteriostatic Water?

The core Bacteriostatic Water formulation has limited apparent patentability. Water for Injection containing benzyl alcohol as a preservative is an old and predictable formulation concept. Composition claims covering the basic product would face substantial novelty and obviousness challenges.

The commercially relevant protection categories are more likely to include:

Protection category	Likely strength	Commercial value
Water plus benzyl alcohol composition	Low	Limited
Defined benzyl alcohol concentration range	Low to moderate	Depends on unexpected stability or safety data
Container-closure system	Moderate	Can protect manufacturing and packaging differentiation
Prefilled syringe or dual-chamber system	Moderate to strong	Higher value if device integration is novel
Drug-specific reconstitution system	Moderate to strong	Depends on formulation and use claims
Manufacturing controls	Low to moderate	Useful as trade secrets and quality systems
Compatibility with a named injectable	Moderate	Requires credible technical data
Method-of-use claims for dilution	Low to moderate	Vulnerable if the use is conventional

No strong product-specific patent barrier is apparent from the established formulation or FDA labeling record. FDA’s Orange Book focuses on approved drug products and listed patent or exclusivity information; it should not be treated as evidence that a generic manufacturer has freedom to operate across all packaging, device, or drug-specific reconstitution claims. [2]

How many patents cover Bacteriostatic Water?

There is no meaningful basis for assigning a large, product-specific patent count to the conventional product. The core formulation does not appear to depend on a dense patent estate comparable to a branded small-molecule drug, long-acting injectable, or biologic.

A freedom-to-operate review would need to separate:

1. the base diluent composition;
2. the vial and stopper system;
3. prefilled delivery devices;
4. drug-specific reconstitution methods;
5. manufacturing and sterilization processes;
6. labeling and administration claims;
7. combination products involving a branded injectable.

A company may have freedom to market standard bacteriostatic water while still infringing a patent covering a particular prefilled syringe, dual-chamber cartridge, or drug-diluent combination.

When does Bacteriostatic Water lose exclusivity?

The conventional product has no obvious single loss-of-exclusivity event comparable to the patent cliff for a branded drug. Commercial entry is driven by regulatory approval, manufacturing capacity, drug-shortage conditions, customer contracts, and quality performance.

Exclusivity type	Relevance
New chemical entity exclusivity	Not applicable to the established formulation
Orphan-drug exclusivity	Not applicable to the base product
Pediatric exclusivity	Product-specific and unlikely to define the market
Listed Orange Book patents	Product-specific; no broad composition barrier is apparent
Trade-secret protection	Relevant to process controls, testing, and supply reliability
Contractual exclusivity	Potentially important in hospital and distributor channels

The absence of a major patent cliff creates a market in which several manufacturers can compete, but sterile manufacturing qualification remains a substantial barrier.

Are there Paragraph IV challenges for Bacteriostatic Water?

Paragraph IV litigation is not expected to be a central market feature for standard Bacteriostatic Water. Paragraph IV certifications are relevant when an abbreviated applicant challenges patents listed for a reference drug in the FDA Orange Book. A conventional bacteriostatic-water entrant would more likely face regulatory and commercial competition than a patent challenge.

Paragraph IV risk can arise in adjacent products, including:

• drug-specific diluent kits;
• prefilled reconstitution syringes;
• dual-chamber systems;
• branded injectable combinations;
• formulations with proprietary excipient ratios;
• device-integrated biologic delivery systems.

The relevant patent analysis must therefore examine the paired drug and delivery system, not only the water product.

What formulation and manufacturing barriers exist?

The main barriers are operational rather than patent-based.

Sterile manufacturing

The product requires validated control of:

• Water for Injection generation and monitoring;
• compounding and bulk-hold times;
• filling and sealing;
• sterilization or aseptic processing;
• environmental monitoring;
• container-closure integrity;
• preservative concentration;
• endotoxin and particulate limits.

Benzyl alcohol does not eliminate the need for sterile manufacturing. The product must maintain sterility through its labeled shelf life and intended use.

Compatibility and stability

Commercial customers may demand data showing that the diluent is compatible with frequently used injectable products. Compatibility can be affected by:

• pH;
• ionic strength;
• protein aggregation;
• precipitation;
• adsorption to container surfaces;
• benzyl-alcohol sensitivity;
• time between reconstitution and administration;
• temperature and light exposure.

A manufacturer can create commercial value by publishing validated compatibility data for high-volume injectables, provided the claims do not exceed the supporting evidence or conflict with the drug sponsor’s labeling.

What commercial opportunities exist for Bacteriostatic Water?

The strongest opportunities are in reliability, specialization, and presentation.

Hospital and clinic supply

Hospitals need dependable access to common diluents. Opportunities include:

• regional sterile-fill capacity;
• dual sourcing for shortage mitigation;
• contract manufacturing;
• private-label products for distributors;
• institutional presentations with barcode and inventory features;
• predictable allocation during injectable-drug shortages.

Supply continuity can support premium pricing even where composition differentiation is limited.

Specialty injectable markets

Growth in peptides, biologics, hormone products, and clinic-administered injectables creates demand for compatible diluents. A supplier can offer drug-specific packaging or co-packaged systems, subject to regulatory review and contractual restrictions.

Home-use and specialty pharmacy channels

Smaller vials, clear instructions, tamper evidence, and integrated administration components may support home-use markets. The product must remain within its approved labeling, and the final injectable drug must authorize the selected diluent and administration process.

International markets

Benzyl alcohol restrictions vary by jurisdiction and patient population. Geographic expansion requires country-specific assessment of:

• preservative limits;
• neonatal warnings;
• pharmacopoeial standards;
• marketing authorization requirements;
• container and labeling rules;
• importation and serialization;
• local sterile manufacturing expectations.

A formulation accepted in the United States may require a different presentation or warning structure elsewhere.

Which companies are competing in the market?

The market has historically included large injectable manufacturers such as Pfizer, through Hospira-branded sterile products, along with other hospital-product and contract-manufacturing suppliers. Competitive positions depend on approved product presentations, manufacturing sites, distributor relationships, and shortage performance.

The relevant competitor comparison is operational:

Competitive factor	Strategic importance
FDA-approved sterile injectable facility	High
Multiple vial sizes	Moderate
Reliable benzyl alcohol assay control	High
Container-closure options	Moderate
Hospital contracts	High
Drug-specific compatibility data	Moderate to high
Shortage history and supply continuity	High
Patent exclusivity	Low for the base formulation

What revenue exposure and launch scenarios should investors assess?

Revenue exposure is usually linked to unit volume rather than high per-unit margins. A supplier’s economics depend on fill-finish utilization, vial procurement, quality costs, freight, and customer concentration.

Three launch scenarios are commercially plausible:

1. Commodity entry: Standard vial presentation, price competition, and distributor-led sales.
2. Reliability-led entry: Premium pricing supported by dual-site manufacturing, shortage supply, and hospital contracts.
3. Specialized entry: Drug-specific or device-integrated presentation with higher development cost and stronger differentiation.

A generic launch is unlikely to cause a dramatic branded-product revenue collapse because the market lacks a large, patent-protected originator premium. Entry would instead pressure price, hospital contracts, and distributor share over time.

How strong is the Bacteriostatic Water patent estate?

The base-product patent estate is weak. The formulation is old, composition differentiation is narrow, and standard use as a diluent is conventional. Stronger protection may exist around a proprietary device, dual-chamber system, validated combination with a particular injectable, or specialized manufacturing process.

Commercial defensibility should therefore be built through:

• regulatory approvals;
• sterile capacity;
• supply contracts;
• validated packaging;
• customer-specific compatibility data;
• quality reputation;
• manufacturing know-how;
• integrated drug-diluent systems.

Patent strategy should focus on genuinely differentiated delivery systems rather than attempting to create broad claims over water and benzyl alcohol.

Key Takeaways

• Bacteriostatic Water for Injection is typically Water for Injection with 0.9% benzyl alcohol.
• The formulation is a preserved diluent, not a therapeutic active ingredient.
• Benzyl alcohol creates important neonatal, intrathecal, and route-specific restrictions.
• The core composition has limited patent strength and no obvious high-value composition barrier.
• Container-closure systems, prefilled formats, and drug-specific reconstitution systems offer better differentiation.
• FDA approval, sterile manufacturing, container integrity, and supply reliability are more important than base-formulation patents.
• Paragraph IV litigation is unlikely to define the standard market.
• Commercial opportunities center on shortage resilience, hospital contracting, specialty injectable compatibility, and integrated delivery systems.
• A preservative-free alternative should be positioned as Sterile Water for Injection, not as Bacteriostatic Water.
• Geographic expansion requires jurisdiction-specific review of benzyl alcohol restrictions, pharmacopoeial standards, and labeling.

FAQs

Is Bacteriostatic Water the same as Sterile Water?

No. Bacteriostatic Water contains a preservative, usually 0.9% benzyl alcohol, while Sterile Water does not.

Can Bacteriostatic Water be used for biologics?

Only when the biologic’s prescribing information permits it. Benzyl alcohol can affect protein stability, aggregation, adsorption, or patient safety.

Is benzyl alcohol a patentable excipient in this product?

Benzyl alcohol itself is not a practical source of broad exclusivity for the established product. Patent value would more likely come from a novel concentration range, delivery system, or validated drug-specific combination.

Can Bacteriostatic Water be sold for neonatal injections?

The product is generally unsuitable for neonates because of benzyl alcohol exposure. A preservative-free diluent may be required, subject to the drug’s labeling and clinical use.

What is the most defensible commercial differentiation strategy?

The strongest strategy is a combination of validated sterile supply, multiple container presentations, robust container-closure performance, drug-specific compatibility data, and integrated reconstitution or delivery systems.

References

1. U.S. Food and Drug Administration. (n.d.). Bacteriostatic Water for Injection, USP: Prescribing information. Pfizer/Hospira labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Water for Injection and related parenteral standards. USP.